Remove tag biologic-medicines
article thumbnail

PharmaShots Weekly Snapshots (May 08 - 12, 2023)

PharmaShots

Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD Date: May 12, 2023 | Tags: Sanofi, Nirsevimab, RSV-Related LRTD, Clinical Trial, P-IIIb, HARMONIE Trial G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023 (..)

FDA 40
article thumbnail

BD partners with Biocorp on connected self-injection devices

pharmaphorum

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Jolly Good/Teijin Pharma develop VR digital therapeutics for depression

pharmaphorum

In 2019 Cognitant and Addenbrook’s Hospital in Cambridge, UK piloted a programme that aimed to educate patients to improve adherence to rheumatoid arthritis medicines. The company halted development before it eventually sold its digital health unit back to Eric Careel, co-founder of Withings, the following year.

Hospitals 119
article thumbnail

Actualising the power of antibody-drug conjugates as cancer therapeutics

European Pharmaceutical Review

ANTIBODY-DRUG conjugates (ADCs) are therapeutic molecules designed as highly targeted medicines with the promise of changing the way we treat cancer and other diseases. tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs. cancer agent or disease-relevant toxin.

article thumbnail

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

pharmaphorum

Because Roche has never applied for Avastin to be used in wet AMD, clinics in the US have had to choose between the peace of mind offered by the regulatory process and Lucentis’ higher price tag, or the unapproved off-label formulation of Avastin at a lower price.

FDA 62
article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. We have the emergence of this new pillar of medicine, which is out of the lab and beyond clinical trials now. But there is that significant challenge. There has been extremely rapid progress.

FDA 59
article thumbnail

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

pharmaphorum

” Biogen meanwhile has been taking flak over its decision to price Aduhelm at $56,000 per year, which looks set to re-ignite debate in the US about the cost of medicines. The post FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag appeared first on.

FDA 98